These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 8174958)

  • 1. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience.
    Connell WR; Kamm MA; Ritchie JK; Lennard-Jones JE
    Gut; 1993 Aug; 34(8):1081-5. PubMed ID: 8174958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations.
    Lewis JD; Abramson O; Pascua M; Liu L; Asakura LM; Velayos FS; Hutfless SM; Alison JE; Herrinton LJ
    Clin Gastroenterol Hepatol; 2009 Nov; 7(11):1195-201; quiz 1141-2. PubMed ID: 19631285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective case series analysis of patients with inflammatory bowel disease on azathioprine. A district general hospital experience.
    Khan ZH; Mayberry JF; Spiers N; Wicks AC
    Digestion; 2000; 62(4):249-54. PubMed ID: 11070408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review.
    Gisbert JP; Gomollón F
    Am J Gastroenterol; 2008 Jul; 103(7):1783-800. PubMed ID: 18557712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity.
    Bernstein CN; Artinian L; Anton PA; Shanahan F
    Dig Dis Sci; 1994 Aug; 39(8):1638-41. PubMed ID: 8050312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in hematologic indices over time in pediatric inflammatory bowel disease treated with azathioprine.
    Soman S; Ashok D; Connolly SA; Cordell SJ; Taylor CJ; Campbell DI
    Drugs R D; 2010; 10(4):213-7. PubMed ID: 21171667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azathioprine and allopurinol: a potentially dangerous combination.
    Venkat Raman G; Sharman VL; Lee HA
    J Intern Med; 1990 Jul; 228(1):69-71. PubMed ID: 2384739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression.
    Peyrin-Biroulet L; Cadranel JF; Nousbaum JB; Oussalah A; Seddik M; Canva V; Cortot A; Sogni P; Gueant JL; Bigard MA; Roblin X; Bronowicki JP
    Aliment Pharmacol Ther; 2008 Oct; 28(8):984-93. PubMed ID: 18657132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease.
    Lowry PW; Franklin CL; Weaver AL; Pike MG; Mays DC; Tremaine WJ; Lipsky JJ; Sandborn WJ
    Gut; 2001 Nov; 49(5):665-70. PubMed ID: 11600469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression.
    Zelinkova Z; Derijks LJ; Stokkers PC; Vogels EW; van Kampen AH; Curvers WL; Cohn D; van Deventer SJ; Hommes DW
    Clin Gastroenterol Hepatol; 2006 Jan; 4(1):44-9. PubMed ID: 16431304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease.
    Cuffari C; Hunt S; Bayless T
    Gut; 2001 May; 48(5):642-6. PubMed ID: 11302961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
    Coenen MJ; de Jong DJ; van Marrewijk CJ; Derijks LJ; Vermeulen SH; Wong DR; Klungel OH; Verbeek AL; Hooymans PM; Peters WH; te Morsche RH; Newman WG; Scheffer H; Guchelaar HJ; Franke B;
    Gastroenterology; 2015 Oct; 149(4):907-17.e7. PubMed ID: 26072396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease].
    Kim JH; Cheon JH; Kim WH
    Korean J Gastroenterol; 2008 May; 51(5):291-7. PubMed ID: 18516013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leucopenia caused by two rifampicin preparations.
    van Assendelft AH
    Eur J Respir Dis; 1984 May; 65(4):251-8. PubMed ID: 6723834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.
    Gisbert JP; Niño P; Rodrigo L; Cara C; Guijarro LG
    Am J Gastroenterol; 2006 Dec; 101(12):2769-76. PubMed ID: 17026564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow function during quadruple immunosuppressive therapy after renal transplantation.
    Heaf J
    Clin Nephrol; 1993 Dec; 40(6):332-8. PubMed ID: 8299241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic toxicosis associated with azathioprine administration in domestic cats.
    Beale KM; Altman D; Clemmons RR; Bolon B
    Am J Vet Res; 1992 Jul; 53(7):1236-40. PubMed ID: 1497196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Frequency of serious adverse events of thiopurine treatment in normal thiopurine S-methyltransferase genotype children with inflammatory bowel disease].
    Tárnok A
    Orv Hetil; 2019 Feb; 160(5):179-185. PubMed ID: 30686035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azathioprine in inflammatory bowel disease, a safe alternative?
    Tanis AA
    Mediators Inflamm; 1998; 7(3):141-4. PubMed ID: 9705598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.